Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DMD Pipeline: After Sarepta’s First-Ever Approval, Are Combinations Next?

Executive Summary

Several companies have DMD drug candidates waiting in the wings to follow Sarepta’s Exondys 51 into the commercial market after FDA approval of the exon-skipping therapy, which could be the backbone for future combination treatment regimens.


Related Content

Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry
Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?
Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows
Santhera Setback Could Have Wide-Reaching Effects For DMD Drugs
Marathon Looking To Go The Distance In DMD
FDA Refuses To File Translarna NDA; PTC Plummets
Akashi Investigating Duchenne Patient Death
BioNotebook: PhaseBio closes $40m Series C round led by AstraZeneca, plus five other VC financings
DMD drug developers stake out territory in rare disease market
Daiichi Sankyo exon-skips into ultra-orphan ring with DMD alliance


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts